CN1882611A - 抗人肿瘤坏死因子α的单克隆抗体的抗体可变区及其编码基因 - Google Patents
抗人肿瘤坏死因子α的单克隆抗体的抗体可变区及其编码基因 Download PDFInfo
- Publication number
- CN1882611A CN1882611A CNA2004800337698A CN200480033769A CN1882611A CN 1882611 A CN1882611 A CN 1882611A CN A2004800337698 A CNA2004800337698 A CN A2004800337698A CN 200480033769 A CN200480033769 A CN 200480033769A CN 1882611 A CN1882611 A CN 1882611A
- Authority
- CN
- China
- Prior art keywords
- variable region
- seq
- heavy chain
- light chain
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title description 11
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 title 1
- 102000057041 human TNF Human genes 0.000 title 1
- 239000013598 vector Substances 0.000 claims abstract description 18
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 12
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 12
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 30
- 239000002299 complementary DNA Substances 0.000 claims description 26
- 239000002773 nucleotide Substances 0.000 claims description 16
- 125000003729 nucleotide group Chemical group 0.000 claims description 16
- 241000588724 Escherichia coli Species 0.000 claims description 13
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 210000004408 hybridoma Anatomy 0.000 description 10
- 238000006062 fragmentation reaction Methods 0.000 description 9
- 238000013467 fragmentation Methods 0.000 description 7
- 230000008521 reorganization Effects 0.000 description 7
- 230000003321 amplification Effects 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 230000010748 Photoabsorption Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 102220369447 c.1352G>A Human genes 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 206010054094 Tumour necrosis Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102220023256 rs387907547 Human genes 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000002437 synoviocyte Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 101710159910 Movement protein Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 102100024147 Protein phosphatase 1 regulatory subunit 14A Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000024835 cytogamy Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- CEAZRRDELHUEMR-UHFFFAOYSA-N gentamicin Chemical class O1C(C(C)NC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N CEAZRRDELHUEMR-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
特异性结合人肿瘤坏死因子-α的单克隆抗体的抗体可变区,含有具有特异性互补决定区的重链可变区和轻链可变区的至少之一。还提供了编码它的核酸分子、含有该核酸分子的重组载体和转化该重组载体的细胞。
Description
发明领域
本发明涉及特异性结合人肿瘤坏死因子-α的单克隆抗体的抗体可变区、编码它的基因、含有该基因的重组载体和转化该重组载体的细胞。
发明背景
人肿瘤坏死因子-α(下文称作“hTNFα”)是由三个17kDa蛋白质亚基组成的同源三聚体(Eck MJ et al.,JBC 267:2119-2122,1992;Smith RA et al.,JBC 262:6951-6954,1987)。hTNFα是由单核细胞和巨噬细胞分泌的炎性细胞因子,在多种细胞反应如坏死和凋亡中作为信号传递物起作用(Beyaert R et al.,FEBS Lett.340:9-16,1994)。
hTNFα产生导致组织破坏的促炎作用,所述组织破坏例如分解软骨和骨(Saklatvala,Nature 322:547-549,1986),以及增加中性粒细胞和淋巴细胞的粘附(Pober et al.,K.Immunol.138:3319,1987)。此外,已知hTNFα在对抗感染性疾病和肿瘤的防御机制中起着重要作用(Fiers W,FEBSLett.285:199-212,1991)。
hTNFα参与炎性疾病、自身免疫病、细菌感染、癌症和退形性病变。在这些疾病中,hTNFα已经被当作特异性生理治疗类风湿性关节炎和节段性回肠炎(Crohn’sdisease)的有用靶蛋白。
同时,还提示使用hTNFα抑制剂来治疗类风湿性关节炎。已经报道hTNFα在分离自早期类风湿性关节的滑膜细胞中过表达(Buchan G et al.,Clin.Exp.Immunol.73:449-455,1988),上述滑膜细胞用抗hTNFα单克隆抗体处理时,与类风湿性关节炎病变相关的细胞因子下降(Butler DM et al.,Eur Cytokine Netw.6:225-230,1995)。
另外,已经发现抗hTNFα抗体或重组可溶性hTNFα受体抑制胶原诱导的小鼠关节炎模型中关节的炎症和破坏(Wpiquet PF et al.,Immunology 77:510-514,1992;Wooley PH et al.,J.Immunol.151:6602-6607,1993;Williams RO et al.,Immnunology84:433-439,1995)。此外,观察到过表达hTNFα的转基因小鼠中诱导了炎性关节炎(Keffer J et al.,EMBO J.10:4025-4031,1991)。
这些结果表明hTNFα作为控制炎性细胞因子的直接或间接调节因子在类风湿性关节炎中起着重要作用。因此,需要开发对hTNFα具有高度选择性和反应性的单克隆抗体来治疗类风湿性关节炎。
发明内容
因此,本发明的一个目的是提供特异性结合hTNFα的单克隆抗体的抗体可变区。
本发明的另一个目的是提供编码特异性结合hTNFα的单克隆抗体的抗体可变区的基因;包含该基因的重组载体;和转化该重组载体的细胞。
根据本发明的一个方面,提供了特异性结合hTNFα的单克隆抗体的抗体可变区,其包含下列至少一种:
包含SEQ ID NO:9、10和11的氨基酸序列的重链可变区;和
包含SEQ ID NO:12、13和14的氨基酸序列的轻链可变区。
根据本发明的另一个方面,提供了编码特异性结合hTNFα的单克隆抗体的重链可变区的核酸分子,其中所述的重链可变区包含SEQ ID NO:9、10和11的氨基酸序列。
根据本发明的另一个方面,提供了编码特异性结合hTNFα的单克隆抗体的轻链可变区的核酸分子,其中所述的轻链可变区包含SEQ ID NO:12、13和14的氨基酸序列。
具体实施方式
本发明涉及特异性结合hTNFα的单克隆抗体的抗体可变区及其编码基因。
为了制备特异性结合hTNFα的单克隆抗体,用重组hTNFα(Biosource PHC3011,Belgium)免疫小鼠。将从免疫小鼠获得的脾细胞与骨髓瘤细胞(Sp2/0-Agl4,ATCCCRL1581)融合,以制备杂交瘤细胞库(pool)。将这种杂交瘤细胞进行后续的克隆和选择程序,以提供多种单克隆抗体。在这些单克隆抗体中,选择特异性结合hTNFα的某些单克隆抗体进行进一步分析。结果,获得了杂交瘤细胞系TSK11,其产生特异性结合hTNFα并对TNFα表现出高度结合亲和力的单克隆抗体。
从杂交瘤细胞系TSK11提取总RNA,进行逆转录酶-聚合酶链式反应(RT-PCR),以合成单克隆抗体重链和轻链的cDNA分子。使用这种cDNA分子作为模板进行聚合酶链式反应(PCR),从而获得编码重链可变区并包括SEQ ID NO:5核苷酸序列的约470bp的cDNA分子;和编码轻链可变区并包括SEQ ID NO:6核苷酸序列的约450bp的cDNA分子。
分析这种重链和轻链可变区的互补决定区(CDR),结果发现重链可变区具有三个CDR,位于SEQ ID NO:7氨基酸序列中的31-35(SEQ ID NO:9)、50-66(SEQID NO:10)和99-106(SEQ ID NO:11)氨基酸位置处。同样,观察到轻链可变区具有三个CDR,位于SEQ ID NO:8氨基酸序列中的24-35(SEQ ID NO:12)、51-57(SEQ ID NO:13)和90-98(SEQ ID NO:14)氨基酸位置处。
因此,根据本发明一个实施方案的cDNA分子编码特异性结合hTNFα的单克隆抗体的重链可变区,其中所述的重链可变区包括SEQ ID NO:9、10和11的氨基酸序列。优选的是,本发明提供了编码含SEQ ID NO:7氨基酸序列的重链可变区的cDNA分子,更优选的是具有SEQ ID NO:5核苷酸序列的cDNA分子。
另外,根据本发明另一个实施方案的cDNA分子编码特异性结合hTNFα的单克隆抗体的轻链可变区,其中所述的轻链可变区包括SEQ ID NO:12、13和14的氨基酸序列。优选的是,本发明提供了编码含SEQ ID NO:8氨基酸序列的轻链可变区的cDNA分子,更优选的是具有SEQ ID NO:6核苷酸序列的cDNA分子。
编码重链可变区和轻链可变区的前述每一种cDNA分子可以插入到传统载体中以获得重组载体。在本发明的一个优选实施方案中,包括SEQ ID NO:5或6核苷酸序列的cDNA分子可以插入到pCR2.1-TOPO(Invitrogen Co.U.S.A)中,以制备含有重链可变区的重组载体pTSK11-Hv,或含有轻链可变区的重组载体pTSK11-Lv。
另外,可以将这种重组载体导入合适的宿主中,如诸如E.coli TOP10F的微生物。例如,用pTSK11-Hv或pTSK11-Lv转化E.coli TOP10F,以获得E.coli转化体,称作E.coli TOP 10F/pTSK11-Hv或E.coli TOP 10F/pTSK11-Lv,它们按照国际承认用于专利程序的微生物保藏布达佩斯条约的条款,于2003年8月26日保藏在KoreanCollection for Type Cultures(地址:#52,Oun-dong,Yusong-ku,Taejon 305-333,Republic ofKorea),保藏编号是KCTC 10514BP或KCTC 10515BP。
上述重组载体可以根据常规方法从转化体中恢复(J.Sambrook et al.,Molecularcloning Vol.1:1.25-1.28)。例如,转化体可以用溶液1(50mM葡萄糖,25mM Tris-HCl和10mM EDTA)处理以弱化其细胞膜,然后用溶液2(0.2N NaOH和1%SDS)处理以完全破坏细胞膜,变性所暴露的蛋白质和染色体。然后,通过进一步用溶液3(5M醋酸钾和醋酸)处理使重组载体之外的细胞组分聚集。然后,将所得的溶液进行离心以获得含重组载体的上清液。重组载体可以通过乙醇沉淀从上清液中回收。
本发明的抗体可变区可以包含下列至少一种:包含SEQ ID NO:9、10和11的氨基酸序列的重链可变区;和包含SEQ ID NO:12、13和14的氨基酸序列的轻链可变区。优选的是,抗体可变区可以包含具有SEQ ID NO:7氨基酸序列的重链可变区和具有SEQ ID NO:8氨基酸序列的轻链可变区中的至少之一。
抗hTNFα的人源化单克隆抗体可以通过将人抗体基因和编码含有SEQ ID NO:9-11所示CDR的重链可变区或编码含有SEQ ID NO:12-14所示CDR的轻链可变区的cDNA分子融合而得到。作为替代方案,人源化单克隆抗体可以将人抗体可变区替换为这种cDNA分子而得到。
如上所述,由于本发明的抗体可变区特异性结合hTNFα,它可以有效地用来中和并灭活hTNFα。
在下列实施例中进一步解释本发明。应理解这些实施例虽然指出了本发明的优选实施方案,但只是以说明方式给出。
实施例1:用hTNFα免疫小鼠
将30μg重组hTNFα(Biosource PHC3011,Belgium)溶解于150μl磷酸缓冲液(PBS)中,和150μl弗氏完全佐剂(Sigma F5881,U.S.A.)混合而乳化。将300μl所得乳液腹腔注射(i.p.)到6周龄雄性BALB/c小鼠体内。两周后,小鼠腹腔注射300μl含30μg hTNFα和150μl弗氏不完全佐剂(Sigma F5506,USA)的乳液混合物。第二次注射两周后,将溶解于150μl PBS中的30μg重组hTNFα静脉注射(i.v.)到小鼠体内。第3次注射10天后,小鼠静脉注射30μg的重组hTNFα的PBS溶液而加强免疫。
实施例2:产生抗hTNFα抗体的小鼠脾细胞的融合
将实施例中免疫的小鼠通过碳酸钾窒息而处死,然后从中摘除脾脏。从小鼠脾脏获得脾细胞,并与非分泌性骨髓瘤细胞Sp2/0(ATCC CRL1581)以10∶1比例混合。为了细胞融合,将预热到37℃的1ml 50%聚乙二醇(PEG 1500,Roche 783641)加到细胞混合物中。将融合细胞用含20%胎牛血清(FBS,JRH,12-10678P)、50μg/ml庆大霉素(Gibco-BRL,15750-060)、1×DMEM(JRH,56499-10L)和1×HAT补充物(0.1mM次黄嘌呤钠、0.4μM氨基蝶呤、16μM胸腺嘧啶;Gibco-BRL,31062-037)的生长培养基稀释,并以1.1×105细胞/孔的浓度、以0.2ml小份分到96孔板(Nunc,469949,Denmark)中。将融合细胞于37℃的湿化CO2孵箱中以5%CO2培养2~3周。
实施例3:产生抗hTNFα抗体的细胞系的筛选和克隆
一旦融合细胞形成集落,就取它们的上清液进行ELISA分析以确证抗体产生。为进行ELISA分析,将孔用1μg/ml hTNFα于4℃包被过夜,向每个孔中加入200μl0.5%酪蛋白-PBS溶液,然后在37℃进行反应1小时。接着,向每个孔中加入100μl上清液,在37℃进行反应2小时。然后,向每个孔中加入100μL以1∶1000比例稀释的偶联辣根过氧化物酶的山羊抗小鼠IgG(Bio-Rad,170-6516),于37℃保持1.5小时。最后,向每个孔中加入100μl辣根过氧化物酶底物溶液(Bio-Rad,172-1064),将这些孔于37℃保持3分钟以诱导显色。用ELISA酶标仪(Dinatec inc.,USA)测定410nm处的光吸收。
实施例4:产生抗hTNFα抗体的细胞系的选择
在实施例3克隆的细胞系中,获得了比获自hTNF-α免疫小鼠的阳性对照血清表现出更高光吸收的9个产生IgG的细胞系。在这些细胞系中,选择表现出最高光吸收的TSK11进行进一步分析。
实施例5:从杂交瘤细胞系TSK11获得的单克隆抗体的同种型分析
通过如下的ELISA分析确认从杂交瘤细胞系产生的单克隆抗体的同种型。向预先包被100μg/ml TSK11抗体的孔中加入100μl的小鼠MonoAb ID kit HRP溶液(Zymed,90-6550),然后,将孔板保持于室温下3分钟,以诱导显色。用ELISA酶标仪(Dinatec inc.,USA)测定410nm处的光吸收。结果发现TSK抗体含有IgG1型重链和κ型轻链。
实施例6:来自杂交瘤细胞系TSK11的单克隆抗体的体外结合亲和力
通过ELISA分析测定抗hTNFα的TSK11抗体的体外结合亲和力。这里,将每个孔用100μl浓度为4μg/ml的重组hTNFα包被。然后,在微管(Micro Tube)(AXYGEN,U.S.A.)中,将重组hTNFα用补充0.02%牛血清白蛋白的PBS稀释,以获得5×10-9M-1×10-10M的终浓度。将各浓度的hTNFα稀释物和30ng TSK11抗体混合,于37℃保持2小时。将混合溶液分到用重组hTNFα包被的每个孔中,于37℃孵育2小时。然后,向每个孔中加入100μl辣根过氧化物酶底物溶液(Bio-rad,172-1064),于37℃保持3分钟以诱导显色。用ELISA酶标仪(Dinatec inc.,USA)测定410nm处的光吸收。
根据Scatchard plot分析(Friguet E.etal.,J.of Immunological Method 77:305-319,1985)计算抑制竞争性ELISA中50%的最大结合所需的抗原浓度的倒数来确定表观亲和力。结果,TSK11对hTNFα的亲和力为1.95×10-9M(Kd)。
实施例7:从杂交瘤细胞系TSK11的RNA分离和cDNA合成
用RNeasy试剂盒(QIAGEN,U.S.A)从杂交瘤细胞系TSK11的1×108细胞中提取总RNA,并使用Thermotranscript试剂盒(GibcoBRL,U.S.A)进行cDNA合成。将作为模板的5μg RNA和0.5ng寡聚d(T)悬浮于蒸馏水中,并将终体积调至10μl。将混合物保持于65℃下5分钟以变性RNA,并冷却到室温以诱导引物退火。用于cDNA合成的RT-PCR反应溶液通过将1μl逆转录酶(1单位/μl)、2.5μl 0.1M DTT、2.5μl 10mM dNTP和1μl RNase抑制剂(1单位/μl)混合而制备,其终体积用蒸馏水调至25μl。RT-PCR反应于50℃进行1小时,通过将反应混合物于95℃加热5分钟而终止。
使用2μg的合成cDNA作为模板和扩增重链的一对引物(SEQ ID NO:1和2)或扩增轻链的另一对引物(SEQ ID NO:3和4)进行PCR。PCR反应溶液含有0.5μlAmpliTaq Gold聚合酶(5单位/μl,Perkin-Elmer Biosystem Co.,U.S.A)、1μl 10mMdNTP和5μl 25mM MgCl2,终体积用蒸馏水调至50μl。PCR条件如下:95℃初始变性5分钟,然后是94℃ 1分钟,55℃ 1分钟,72℃ 2分钟的30个循环,接着于72℃最终延伸10分钟。
将扩增的DNA进行1.5%琼脂糖凝胶电泳,将凝胶用100ml的0.5μg/ml溴化乙锭溶液染色20分钟。结果,鉴定到了两个扩增的DNA产物,对于重链在对应于约470bp的位置处,对于轻链在对应于约450bp的位置处,参照100bp的标准DNAladder(Lifetechnology Co.U.S.A.)。
实施例8:cDNA克隆
利用QIAquick Gel Extraction试剂盒(Qiagen,U.S.A.)从琼脂糖凝胶回收并纯化实施例7中扩增的470bp的重链DNA片段。将纯化的DNA片段亚克隆到载体pCR2.1-TOPO(Invitrogen Co.,U.S.A.)中,将所得的载体导入E.coli TOP10F(Invitrogen Co.,U.S.A.),以获得转化体(Cohen,S.N.et al.,Proc.Nat.Acad.Sci.69:2110,1972)。如此制备的E.coli转化体在补充100μg/ml氨苄青霉素的LB培养基中培养过夜。从培养的转化体中提取质粒DNA,并用限制酶EcoRI(BioLab Co.,USA)处理,以获得含470bp重链DNA片段的克隆TSK11-Hv。
对于实施例7中扩增的450bp的轻链DNA片段进行同样的程序,以获得E.coliTOP10F转化体。E.coli转化体在补充100μg/ml氨苄青霉素的LB培养基中培养过夜。从培养的转化体中提取质粒DNA,并用限制酶EcoRI(BioLab Co.,USA)处理,以获得含450bp轻链DNA片段的克隆TSK11-Lv。
实施例9:cDNA核苷酸测序
使用Wizard plus SV Minipreps DNA Purification System(Promega,U.S.A.)纯化实施例8中获得的克隆TSK11-Hv和TSK11-Lv,并进行核苷酸测序。
结果发现获得的重链DNA片段含有SEQ ID NO:5核苷酸序列和SEQ ID NO:7氨基酸序列。验证了属于克隆TSK11Hv的三个具体DNA片段(TSK11Hv1、TSK11Hv2和TSK11Hv3),它们的核苷酸序列相同。从克隆TSK11Hv获得的质粒载体命名为pTSK11-Hv。另外,具有质粒载体pTSK11-Hv的E.coli转化体命名为E.coli TOP10F/pTSK11-Hv,按照国际承认用于专利程序的微生物保藏布达佩斯条约的条款,于2003年8月26日保藏在Korean Collection for Type Cultures(地址:#52,Oun-dong,Yusong-ku,Taejon 305-333,Republic of Korea),保藏编号是KCTC10514BP。
另外,发现获得的轻链DNA片段含有SEQ ID NO:6核苷酸序列和SEQ ID NO:8氨基酸序列。验证了属于克隆TSK11Lv的两个具体DNA片段(TSK11Lv1和TSK11Lv3),它们的核苷酸序列相同。从克隆TSK11Lv获得的质粒载体命名为pTSK11-Lv。另外,具有质粒载体pTSK11-Lv的E.coli转化体命名为E.coliTOP10F/pTSK11-Lv,按照国际承认用于专利程序的微生物保藏布达佩斯条约的条款,于2003年8月26日保藏在Korean Collection for Type Cultures(地址:#52,Oun-dong,Yusong-ku,Taejon 305-333,Republic of Korea),保藏编号是KCTC10515BP。
根据从杂交瘤细胞系TSK11获得的单克隆抗体可变区的氨基酸序列分析(Harris.L.et al.,Protein Sci.4:306-310,1995;Kabat.E.A.et al.,Sequence ofproteins of immunological interest.5th Ed.,1991;Williams A.F.et al.,Annu.Rev.Immunol.6:381-406,1988),发现重链属于由Kabat定义的11类之外的混杂类,轻链属于κ6-型亚类。
重链中识别抗原的CDR发现位于氨基酸位置31-35(SEQ ID NO:9)、50-66(SEQID NO:10)和99-106(SEQ ID NO:11),轻链中识别抗原的CDR发现位于氨基酸位置24-35(SEQ ID NO:12)、51-57(SEQ ID NO:13)和90-98(SEQ ID NO:14)。
虽然描述并说明了本发明的实施方案,显而易见的是,可以在不背离本发明实质的情况下进行各种改变和改进,本发明实质仅受所附权利要求范围的限定。
序列表
<110>(株)柳韩洋行
<120>抗人肿瘤坏死因子α的单克隆抗体的抗体可变区及其编码基因
<130>PCA41171-YUH
<150>KR 10-2003-0080950
<151>2003-11-17
<160>14
<170>Kopatentin 1.71
<210>1
<211>39
<212>DNA
<213>人工序列
<220>
<223>重链正向引物
<400>1
actagtcgac atggcttggg tgtggaactt gccattcct 39
<210>2
<211>35
<212>DNA
<213>人工序列
<220>
<223>重链反向引物
<400>2
cccaagcttc caggggccag gggatagacg ggtgg 35
<210>3
<211>39
<212>DNA
<213>人工序列
<220>
<223>轻链正向引物
<400>3
actagtcgac atggatttac aagtgcagat tttcagctt 39
<210>4
<211>30
<212>DNA
<213>人工序列
<220>
<223>轻链反向引物
<400>4
cccaagctta ctggatggtg ggaagatgga 30
<210>5
<211>351
<212>DNA
<213>编码重链可变区的cDNA分子的核苷酸序列
<400>5
caggtccagt tggtgcagtc tggacctgag ctgaagaagc ctggagagac agtcaagatc 60
tcctgcaagg cttctggata taccttcaca cactatggaa tgaactgggt gaagcaggct 120
ccaggagagg gtttaaagtg gatgggctgg ataaacacca acactggaga gccaagatat 180
gatgaagagt tcaagggacg gtttgccttc tctttggaaa cctctgccag cactgcctat 240
ttacagatca acaacctcag acgtgaggac acggctacat atttctgtgc aagatatgat 300
tccaggggat ttgactgctg gggccaaggc accactctca cagtctcctc a 351
<210>6
<211>327
<212>DNA
<213>编码轻链可变区的cDNA分子的核苷酸序列
<400>6
caaattgttc tcacccagtc tccagcaatc atgtctgcat ctctagggga acgggtcacc 60
atgacctgca ctgccagctc aagtataagt tacaattact ttcactggta tcagcagagg 120
ccaggatcct cccccaaact ctggatttat agctcatcca atctggcttc tggagtccca 180
cctcgcatca gtggcagtgg gtctgggacc tcttactctc tcacaatcag cagcatggag 240
gctgaagatg ctgccactta ttactgccac cagtatgagc gttccccgtg gacgttcggt 300
ggaggcacca agctggaaat caaacgg 327
<210>7
<211>117
<212>PRT
<213>编码重链可变区的cDNA分子的氨基酸序列
<400>7
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
1 5 10 15
Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr His Tyr
20 25 30
Gly Met Asn Trp Val Lys Gln Ala Pro Gly Glu Gly Leu Lys Trp Met
35 40 45
Gly Trp Ile Asn Thr Asn Thr Gly Glu Pro Arg Tyr Asp Glu Glu Phe
50 55 60
Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr
65 70 75 80
Leu Gln Ile Asn Asn Leu Arg Arg Glu Asp Thr Ala Thr Tyr Phe Cys
85 90 95
Ala Arg Tyr Asp Ser Arg Gly Phe Asp Cys Trp Gly Gln Gly Thr Thr
100 105 110
Leu Thr Val Ser Ser
115
<210>8
<211>109
<212>PRT
<213>编码轻链可变区的cDNA分子的氨基酸序列
<400>8
Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly
1 5 10 15
Glu Arg Val Thr Met Thr Cys Thr Ala Ser Ser Ser Ile Ser Tyr Asn
20 25 30
Tyr Phe His Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Lys Leu Trp
35 40 45
Ile Tyr Ser Ser Ser Asn Leu Ala Ser Gly Val Pro Pro Arg Ile Ser
50 55 60
Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu
65 70 75 80
Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Tyr Glu Arg Ser Pro
85 90 95
Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg
100 105
<210>9
<211>5
<212>PRT
<213>重链CDR1
<400>9
His Tyr Gly Met Asn
1 5
<210>10
<211>17
<212>PRT
<213>重链CDR2
<400>10
Trp Ile Asn Thr Asn Thr Gly Glu Pro Arg Tyr Asp Glu Glu Phe Lys
1 5 10 15
Gly
<210>11
<211>8
<212>PRT
<213>重链CDR3
<400>11
Tyr Asp Ser Arg Gly Phe Asp Cys
1 5
<210>12
<211>12
<212>PRT
<213>轻链CDR1
<400>12
Thr Ala Ser Ser Ser Ile Ser Tyr Asn Tyr Phe His
1 5 10
<210>13
<211>7
<212>PRT
<213>轻链CDR2
<400>13
Ser Ser Ser Asn Leu Ala Ser
1 5
<210>14
<211>9
<212>PRT
<213>轻链CDR3
<400>14
His Gln Tyr Glu Arg Ser Pro Trp Thr
1 5
Claims (15)
1.特异性结合人肿瘤坏死因子-α的单克隆抗体的抗体可变区,包含下列至少一种:
包含SEQ ID NO:9、10和11的氨基酸序列的重链可变区;和
包含SEQ ID NO:12、13和14的氨基酸序列的轻链可变区。
2.权利要求1的抗体可变区,其中所述的重链可变区包含SEQ ID NO:7的氨基酸序列。
3.权利要求1的抗体可变区,其中所述的轻链可变区包含SEQ ID NO:8的氨基酸序列。
4.权利要求1的抗体可变区,其中所述的重链可变区由包含SEQ ID NO:5的核苷酸序列的cDNA分子编码。
5.权利要求1的抗体可变区,其中所述的轻链可变区由包含SEQ ID NO:6的核苷酸序列的cDNA分子编码。
6.编码特异性结合人肿瘤坏死因子-α的单克隆抗体的重链可变区的核酸分子,其中所述的重链可变区包含SEQ ID NO:9、10和11的氨基酸序列。
7.权利要求6的核酸分子,其中所述的重链可变区包含SEQ ID NO:7的氨基酸序列。
8.权利要求6的核酸分子,其包含SEQ ID NO:5的核苷酸序列。
9.编码特异性结合人肿瘤坏死因子-α的单克隆抗体的轻链可变区的核酸分子,其中所述的轻链可变区包含SEQ ID NO:12、13和14的氨基酸序列。
10.权利要求9的核酸分子,其中所述的轻链可变区包含SEQ ID NO:8的氨基酸序列。
11.权利要求9的核酸分子,其包含SEQ ID NO:6的核苷酸序列。
12.包含权利要求6的核酸分子的重组载体pTSK11-Hv。
13.包含权利要求9的核酸分子的重组载体pTSK11-Lv。
14.转化体E.coli TOP 10F/pTSK11-Hv,其保藏编号为KCTC 10514BP,转化有权利要求12的重组载体pTSK11-Hv。
15.转化体E.coli TOP 10F/pTSK11-Lv,其保藏编号为KCTC 10515BP,转化有权利要求13的重组载体pTSK11-Lv。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030080950A KR100772800B1 (ko) | 2003-11-17 | 2003-11-17 | 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자 |
KR1020030080950 | 2003-11-17 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008100062708A Division CN101440131B (zh) | 2003-11-17 | 2004-11-16 | 抗人肿瘤坏死因子α的单克隆抗体的抗体可变区及其编码基因 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1882611A true CN1882611A (zh) | 2006-12-20 |
Family
ID=36640673
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008100062708A Expired - Fee Related CN101440131B (zh) | 2003-11-17 | 2004-11-16 | 抗人肿瘤坏死因子α的单克隆抗体的抗体可变区及其编码基因 |
CNA2004800337698A Pending CN1882611A (zh) | 2003-11-17 | 2004-11-16 | 抗人肿瘤坏死因子α的单克隆抗体的抗体可变区及其编码基因 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008100062708A Expired - Fee Related CN101440131B (zh) | 2003-11-17 | 2004-11-16 | 抗人肿瘤坏死因子α的单克隆抗体的抗体可变区及其编码基因 |
Country Status (8)
Country | Link |
---|---|
US (2) | US7109320B2 (zh) |
EP (1) | EP1692179B1 (zh) |
JP (1) | JP4563397B2 (zh) |
KR (1) | KR100772800B1 (zh) |
CN (2) | CN101440131B (zh) |
AT (1) | ATE482980T1 (zh) |
DE (1) | DE602004029394D1 (zh) |
WO (1) | WO2005047329A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008141511A1 (fr) * | 2007-05-22 | 2008-11-27 | Human Antibodomics (Shanghai) Inc. | ANTICORPS MONOCLONAL HUMAIN ANTI-TNFα ET SON UTILISATION |
WO2010105446A1 (zh) * | 2009-03-20 | 2010-09-23 | 上海宏源生物技术有限公司 | 抗人肿瘤坏死因子受体α单抗及其应用 |
CN102464718A (zh) * | 2010-11-05 | 2012-05-23 | 财团法人工业技术研究院 | 人源化之单克隆抗体、其氨基酸序列与核苷酸序列与其用途 |
US8691226B2 (en) | 2010-10-20 | 2014-04-08 | Industrial Technology Research Institute | Humanized anti-human tumor necrosis factor alpha monoclonal antibody and sequence thereof |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101111521B (zh) * | 2004-12-29 | 2011-08-24 | 株式会社柳韩洋行 | 肿瘤坏死因子-α特异性人源化抗体 |
EP2084188A2 (en) * | 2006-10-12 | 2009-08-05 | Genentech, Inc. | Antibodies to lymphotoxin-alpha |
CN101177453B (zh) * | 2006-11-07 | 2010-09-29 | 旭华(上海)生物研发中心有限公司 | 抗人肿瘤坏死因子α的重组嵌合抗体 |
US8658171B2 (en) | 2011-02-28 | 2014-02-25 | Livzon Mabpharm Inc. | Humanized anti-TNFα antibodies |
CN102675460B (zh) | 2011-02-28 | 2015-08-19 | 珠海市丽珠单抗生物技术有限公司 | 抗肿瘤坏死因子α的人源化抗体 |
CN103173457B (zh) * | 2013-03-04 | 2015-01-28 | 百奇生物科技(苏州)有限公司 | 抗cd20单克隆抗体可变区序列及其制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6280825B1 (en) | 1988-12-07 | 2001-08-28 | Laminating Technologies, Inc. | Method of making a composite of paper and plastic film and composites |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB9028123D0 (en) * | 1990-12-28 | 1991-02-13 | Erba Carlo Spa | Monoclonal antibodies against human tumor necrosis factor alpha |
CN1300173C (zh) * | 1996-02-09 | 2007-02-14 | 艾博特生物技术有限公司 | 结合人TNFα的人抗体 |
GB0013810D0 (en) * | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
CN1280190A (zh) * | 2000-07-14 | 2001-01-17 | 中国人民解放军第四军医大学 | 重组的抗人TNFα基因工程抗体及其制备方法 |
CN101111521B (zh) * | 2004-12-29 | 2011-08-24 | 株式会社柳韩洋行 | 肿瘤坏死因子-α特异性人源化抗体 |
-
2003
- 2003-11-17 KR KR1020030080950A patent/KR100772800B1/ko active IP Right Grant
-
2004
- 2004-11-16 CN CN2008100062708A patent/CN101440131B/zh not_active Expired - Fee Related
- 2004-11-16 AT AT04800099T patent/ATE482980T1/de not_active IP Right Cessation
- 2004-11-16 DE DE602004029394T patent/DE602004029394D1/de active Active
- 2004-11-16 CN CNA2004800337698A patent/CN1882611A/zh active Pending
- 2004-11-16 JP JP2006539402A patent/JP4563397B2/ja not_active Expired - Fee Related
- 2004-11-16 WO PCT/KR2004/002964 patent/WO2005047329A1/en active Application Filing
- 2004-11-16 US US10/988,617 patent/US7109320B2/en not_active Expired - Fee Related
- 2004-11-16 EP EP04800099A patent/EP1692179B1/en not_active Not-in-force
-
2006
- 2006-03-16 US US11/376,338 patent/US7196177B2/en not_active Expired - Fee Related
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008141511A1 (fr) * | 2007-05-22 | 2008-11-27 | Human Antibodomics (Shanghai) Inc. | ANTICORPS MONOCLONAL HUMAIN ANTI-TNFα ET SON UTILISATION |
WO2010105446A1 (zh) * | 2009-03-20 | 2010-09-23 | 上海宏源生物技术有限公司 | 抗人肿瘤坏死因子受体α单抗及其应用 |
US8691226B2 (en) | 2010-10-20 | 2014-04-08 | Industrial Technology Research Institute | Humanized anti-human tumor necrosis factor alpha monoclonal antibody and sequence thereof |
CN102464718A (zh) * | 2010-11-05 | 2012-05-23 | 财团法人工业技术研究院 | 人源化之单克隆抗体、其氨基酸序列与核苷酸序列与其用途 |
CN102464718B (zh) * | 2010-11-05 | 2014-08-13 | 财团法人工业技术研究院 | 人源化之单克隆抗体、其氨基酸序列与核苷酸序列与其用途 |
Also Published As
Publication number | Publication date |
---|---|
CN101440131B (zh) | 2013-02-06 |
EP1692179A4 (en) | 2007-10-31 |
JP2007530012A (ja) | 2007-11-01 |
EP1692179B1 (en) | 2010-09-29 |
EP1692179A1 (en) | 2006-08-23 |
JP4563397B2 (ja) | 2010-10-13 |
KR20050047182A (ko) | 2005-05-20 |
US20050124041A1 (en) | 2005-06-09 |
US7196177B2 (en) | 2007-03-27 |
DE602004029394D1 (de) | 2010-11-11 |
CN101440131A (zh) | 2009-05-27 |
KR100772800B1 (ko) | 2007-11-01 |
WO2005047329A1 (en) | 2005-05-26 |
ATE482980T1 (de) | 2010-10-15 |
US20060147452A1 (en) | 2006-07-06 |
US7109320B2 (en) | 2006-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1289671C (zh) | 对人肿瘤坏死因子α具有特异性的抗体分子及其用途 | |
US10344084B2 (en) | IL-17 antagonistic antibodies | |
US9481731B2 (en) | Toll-like receptor 3 antagonists | |
CN1898264A (zh) | 用新的抗il13单克隆抗体治疗癌症 | |
CN1878793A (zh) | 拮抗hmgb1的单克隆抗体 | |
CN1395581A (zh) | 抗人IL-1β抗体 | |
CN1585778A (zh) | 修饰的抗-TNFα抗体 | |
CN1878790A (zh) | 可中和的hgf表位和与其结合的中和抗体 | |
WO2014194274A2 (en) | Oncostatin m receptor antigen binding proteins | |
CN1882611A (zh) | 抗人肿瘤坏死因子α的单克隆抗体的抗体可变区及其编码基因 | |
CN101076543A (zh) | 用于治疗和诊断变性神经疾病如阿尔茨海默症的单结构域骆驼抗淀粉样蛋白β的抗体以及包含它的多肽 | |
CN1489473A (zh) | 沉默型抗cd-28抗体及其应用 | |
CN1289668C (zh) | 一种用于抗体改形的体外分子定向进化方法 | |
CN1878792A (zh) | Nogo-a结合分子及其药物用途 | |
CN1775808A (zh) | 用于靶向结合淋巴细胞白血病细胞的抗cd19的工程抗体及其用途 | |
CN101039960A (zh) | 抗il-13的嵌合人源化单克隆抗体 | |
CN1176106C (zh) | 抗人胃癌单链抗体及其应用 | |
CN1849338A (zh) | 针对白介素-1受体的抗体及其应用 | |
EA041171B1 (ru) | Антитела к рецептору онкостатина m и их применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |